Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

BACKGROUND: In the global FLAURA study, first-line osimertinib, a third-generation irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly improved progression-free survival (PFS) and overall survival (OS) versus comparator EGFR TKIs in patients with EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, He, Yong, Li, Wei, Zhang, He-long, Zhou, Qing, Wang, Buhai, Liu, Chunling, Walding, Andrew, Saggese, Matilde, Huang, Xiangning, Fan, Minhao, Wang, Jia, Ramalingam, Suresh S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935816/
https://www.ncbi.nlm.nih.gov/pubmed/33544337
http://dx.doi.org/10.1007/s11523-021-00794-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935816/
https://www.ncbi.nlm.nih.gov/pubmed/33544337
http://dx.doi.org/10.1007/s11523-021-00794-6

Ejemplares similares